Undisclosed anti-CCR8 antibody / iBio - LARVOL DELTA

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development (GlobeNewswire) - "The anti-EGFRvIII antibody was specially engineered to enhance its ability to attack cancer cells and has proven effective in a mouse model for head and neck cancer. In preclinical studies, iBio’s anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals. iBio developed the antibody using its patented AI epitope steering technology....In addition to the anti-EGFR program, iBio’s CCR8 antibody has proven effective in a mouse model for colon cancer. Preclinical studies show the anti-CCR8 molecule inhibited tumor growth and achieved a 22 percent reduction in tumor size compared to its pre-treatment dimensions. Using its patented AI epitope steering platform, iBio specifically engineered the anti-CCR8 molecule to enhance its ability to attack cancer cells without affecting its close relative, CCR4, even though their binding regions are highly similar."

Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor